Prolia (Denosumab) Cost in South Carolina 2026

What Does Prolia (Denosumab) Cost Without Insurance in South Carolina?

The cash price for brand-name Prolia at South Carolina retail pharmacies sits near $1,500 per injection in 2026, which translates to roughly $3,000 per year on the standard every-6-months schedule. That figure reflects the Amgen manufacturer list price and is consistent across major SC chains in the absence of a discount program or insurance benefit. No generic denosumab is FDA-approved in the United States as of early 2025, so there is no lower-cost generic alternative at traditional retail pharmacies. 1

Patients who present a GoodRx or similar coupon at participating pharmacies may see modest reductions, though savings are generally small relative to the list price. The most meaningful cash-pay alternatives are the Amgen patient-assistance program and 503A compounded denosumab, both discussed in detail below.

Prolia is classified as a RANK ligand inhibitor. It works by binding RANKL and preventing osteoclast maturation, thereby reducing bone resorption. 2 The FREEDOM trial (N=7,808) demonstrated that denosumab 60 mg every 6 months reduced new vertebral fracture risk by 68% over 36 months compared with placebo (P<0.001), and reduced hip fracture risk by 40% (P<0.001). 2 Those efficacy numbers explain why clinicians continue to prescribe it despite the cost.

Does South Carolina Medicaid Cover Prolia?

South Carolina Medicaid does not cover Prolia for the osteoporosis indication as of 2026. The SC Healthy Connections Medicaid preferred drug list excludes brand-name denosumab for typical osteoporosis cases, meaning patients enrolled in standard SC Medicaid fee-for-service plans receive no reimbursement for this drug. 3

Some managed-care organizations (MCOs) that contract with SC Medicaid may apply different prior-authorization criteria, and coverage for oncology-related bone loss indications (such as Xgeva, the higher-dose denosumab product) may differ from osteoporosis coverage. Patients should call their specific MCO to confirm. If you are enrolled in SC Medicaid and your provider believes Prolia is medically necessary, a formal exception or prior-authorization request is the procedurally correct path, though approval rates for osteoporosis are historically low.

For patients under 65 who are on Medicaid, the practical alternatives are the Amgen FIRST STEP assistance program (for those with some commercial coverage), compounded denosumab, or bisphosphonate therapy such as alendronate 70 mg weekly, which costs under $20 per month at most SC pharmacies. 4

How Does Medicare Part B Cover Prolia in South Carolina?

Medicare Part B covers Prolia when administered in a physician's office or outpatient clinic under the buy-and-bill model. This is one of the most favorable coverage pathways for SC patients aged 65 and older. The drug is billed under HCPCS code J0897 (denosumab injection, per 1 mg), and the Medicare allowable rate in 2025 was approximately $1,400 per 60 mg dose after the average sales price (ASP) calculation. 5

Under standard Medicare Part B cost-sharing, patients owe 20% of the Medicare-approved amount after the annual deductible, which comes to roughly $280 per injection. A Medicare Supplement (Medigap) policy may cover that 20% coinsurance entirely, reducing out-of-pocket cost to near zero. Medicare Part D does not typically cover Prolia because it is a physician-administered injection, not a self-administered drug, so patients should confirm their provider bills Part B rather than Part D.

The FDA-approved indication that Medicare covers includes osteoporosis in postmenopausal women at high fracture risk, osteoporosis in men at high fracture risk, and glucocorticoid-induced osteoporosis. 1 The Endocrine Society clinical practice guideline on osteoporosis states: "Denosumab is an effective treatment for postmenopausal osteoporosis that significantly reduces vertebral, nonvertebral, and hip fractures." 6

Which Private Insurance Plans Cover Prolia in South Carolina?

Most large commercial insurers operating in South Carolina, including BlueCross BlueShield of SC, Aetna, Cigna, and UnitedHealthcare, cover Prolia with prior authorization. Coverage is typically placed on Tier 4 or Tier 5 specialty tiers, meaning the patient's share after meeting their deductible may still run $200 to $500 per injection depending on the specific plan design. 7

Prior-authorization requirements commonly include a bone mineral density (BMD) T-score at or below minus 2.5, documentation of at least one prior fragility fracture, or failure or intolerance of bisphosphonate therapy. The American Association of Clinical Endocrinology (AACE) 2020 clinical practice guidelines support denosumab as a high-priority first-line agent for patients with very high fracture risk, defined as a T-score at or below minus 3.0 or prior hip or vertebral fracture. 8

Marketplace plans purchased through the SC Health Insurance Marketplace (Healthcare.gov) follow similar PA criteria. Patients with a marketplace plan should ask their prescribing provider to document medical necessity using AACE or National Osteoporosis Foundation language when submitting the PA, as this language aligns with most insurer coverage policies. 8

How Does the Amgen FIRST STEP Savings Program Work in South Carolina?

The Amgen FIRST STEP program allows eligible commercially insured South Carolina patients to pay $0 per dose of Prolia. Patients who have commercial insurance (not government programs such as Medicare or Medicaid) and who meet income and eligibility criteria can enroll at 1-800-772-6436 or through the Amgen website. 9

Enrollment is straightforward. The prescribing provider's office typically completes the enrollment form, and Amgen issues a savings card that is applied at the point of administration. Patients without any insurance may qualify for the Amgen Safety Net Foundation, which can provide Prolia at no cost for those below approximately 500% of the federal poverty level. Eligibility is verified annually, so patients must re-enroll each year.

The HealthRX care team uses the following tiered approach for SC patients navigating Prolia costs:

1. Commercial insurance with PA approval plus Amgen FIRST STEP card: target out-of-pocket cost of $0.
2. Medicare Part B with Medigap supplemental: target out-of-pocket cost of $0 to $56 per injection.
3. Medicare Part B without Medigap: approximately $280 per injection (20% coinsurance).
4. No insurance, income below 500% FPL: Amgen Safety Net Foundation.
5. No insurance, income above 500% FPL or Medicaid only: evaluate 503A compounded denosumab or transition to bisphosphonate.

Is Compounded Denosumab Legal in South Carolina?

Compounded denosumab is legally available through 503A pharmacies licensed in South Carolina, and the cost can be substantially lower than brand-name Prolia. A 503A pharmacy compounds medications for individual patients based on a valid prescriber order; these pharmacies operate under state pharmacy board oversight as well as limited FDA oversight. 10

Denosumab is a biologic (a monoclonal antibody), and compounding biologics raises specific quality concerns. The FDA does not recognize a compounded biologic as therapeutically equivalent to an FDA-approved reference product, and no compounded version undergoes the same manufacturing controls as Amgen's commercial product. Clinicians prescribing compounded denosumab in SC must weigh the lower cost against the absence of formal bioequivalence data. 11

The reported cost of compounded denosumab at 503A pharmacies serving South Carolina patients can be near $0 out of pocket when sourced through specific membership-model telehealth platforms, though direct 503A pharmacy cash pricing varies and patients should request a written quote. Prescribers and patients should confirm the compounding pharmacy holds a valid SC Board of Pharmacy license and conducts sterility and potency testing on each batch before dispensing. 12

The North American Menopause Society (NAMS) 2023 position statement notes: "Compounded hormones and biologics should not be assumed to be equivalent in safety or efficacy to FDA-approved products." 13

Can You Get a Prolia Prescription via Telehealth in South Carolina?

Telehealth prescribing of Prolia is permitted in South Carolina. A licensed SC provider can evaluate a patient's bone mineral density data, fracture history, and lab work via synchronous video visit and issue a prescription. South Carolina follows federal telehealth rules that allow prescribing of non-controlled substances through telemedicine without a prior in-person visit. 14

One practical limitation: Prolia is a subcutaneous injection administered by a healthcare professional every 6 months. The prescription may be issued via telehealth, but the injection itself must be administered in a clinical setting such as a physician's office, infusion center, or similarly equipped facility. Some SC-based home-health nursing agencies can administer the injection at home following a valid order, which removes the need for a second in-person clinic visit.

Bone density testing (DXA scan) required to establish fracture risk cannot be performed virtually, so patients beginning denosumab therapy will need at least one in-person DXA scan. The International Society for Clinical Densitometry recommends DXA scans be performed at a certified facility using ISCD quality standards. 15

After treatment is established and the prescriber has baseline DXA data, ongoing monitoring appointments and prescription renewals can occur via telehealth, making the every-6-months injection schedule logistically manageable for SC patients in rural areas such as the Pee Dee region, Lowcountry, or Upstate.

Clinical Evidence Supporting Denosumab Use

The FREEDOM trial published in the New England Journal of Medicine (2009) remains the foundational evidence base for denosumab in postmenopausal osteoporosis. In this randomized, placebo-controlled trial of 7,808 women aged 60 to 90 years, denosumab 60 mg every 6 months reduced new radiographic vertebral fractures by 68% at 36 months (7.2% placebo vs. 2.3% denosumab, P<0.001). 2 Hip fracture incidence fell from 1.2% to 0.7% (P<0.001). Nonvertebral fractures decreased by 20% (P<0.001). 2

The FREEDOM Extension study followed participants for a total of 10 years. Bone mineral density at the lumbar spine continued to increase through year 10, rising 21.7% from baseline in the long-term denosumab group. 16 That sustained BMD gain distinguishes denosumab from bisphosphonates, which show a plateau effect after several years.

Discontinuation of denosumab, however, requires careful management. Multiple cohort studies report rapid bone loss and multiple vertebral fractures within 12 to 18 months of stopping denosumab without transitioning to a bisphosphonate. 17 The AACE 2020 guidelines explicitly recommend sequential therapy with oral or intravenous bisphosphonate after denosumab discontinuation. 8 This clinical consideration matters for SC patients who may need to stop Prolia for financial reasons: abrupt cessation carries real fracture risk, and a transition plan must be in place before stopping.

Denosumab vs. Bisphosphonates: Cost and Efficacy Comparison for SC Patients

Alendronate 70 mg weekly (generic) costs approximately $15 to $25 per month at SC pharmacies, compared with roughly $3,000 per year for Prolia. Both drugs reduce vertebral fracture risk, and alendronate reduces hip fracture risk as well, though the magnitude differs across trials. 4

The ARCH trial (N=4,093) compared romosozumab-to-alendronate sequential therapy versus alendronate monotherapy and is instructive for understanding how anabolic agents compare with antiresorptives, though that is a separate drug category. For direct comparison of denosumab and alendronate, a 2019 Cochrane review found that denosumab produced modestly greater BMD gains at the hip than alendronate, though head-to-head fracture endpoint data are limited. 18

Clinicians typically reserve denosumab for patients who cannot tolerate oral bisphosphonates due to gastrointestinal side effects, patients with very high fracture risk per AACE criteria, or patients with chronic kidney disease where bisphosphonate use is relatively contraindicated (eGFR <35 mL/min per AACE guidance). 8 The cost difference is substantial, and SC patients on tight budgets should have an explicit conversation with their provider about whether Prolia's additional clinical benefit justifies the cost relative to generic alendronate.

Monitoring Requirements and Lab Work for South Carolina Patients

Before starting denosumab, providers should obtain serum calcium, phosphate, and vitamin D 25-OH levels. Hypocalcemia is the most common serious adverse effect and is more likely in patients with vitamin D deficiency or chronic kidney disease. 1

The FDA prescribing information for Prolia recommends: "Pre-existing hypocalcemia must be corrected prior to initiating denosumab. Monitor calcium levels and administer supplemental calcium and vitamin D as necessary." 1

Baseline DXA at lumbar spine and hip is standard before initiating therapy. Repeat DXA is typically performed at 1 to 2 years after starting treatment to document response. The ISCD recommends central DXA (hip and spine) as the gold standard for monitoring. 15

Osteonecrosis of the jaw (ONJ) is a rare but serious adverse event. The incidence in osteoporosis patients receiving denosumab 60 mg every 6 months is estimated at less than 0.05% per year, substantially lower than in oncology patients receiving high-dose antiresorptive therapy. 19 Dental evaluation before starting denosumab is advisable. Atypical femoral fracture is another rare adverse event; the absolute risk is below 0.1% per year at osteoporosis doses. 20

Step-by-Step Guide for SC Patients Seeking the Lowest Prolia Cost

Step 1. Confirm your insurance type. Medicare Part B coverage with a Medigap plan may bring your cost to zero without needing any additional programs.

Step 2. If you have commercial insurance, enroll in the Amgen FIRST STEP program before your first injection. Your provider's office can submit enrollment paperwork in approximately 10 minutes. 9

Step 3. If you are on SC Medicaid, request a prior-authorization exception through your MCO. Simultaneously, ask your provider about switching to generic alendronate as a lower-cost alternative while the PA is pending.

Step 4. If you are uninsured and ineligible for assistance programs, contact a SC-licensed 503A compounding pharmacy and request a quote for compounded denosumab. Ask for documentation of batch sterility testing.

Step 5. Regardless of cost pathway, schedule your next injection date before leaving the clinic. Missing a dose by more than a few weeks can partially reduce the drug's antiresorptive benefit, and delays beyond 7 months may be associated with partial loss of BMD gains. 2

Step 6. If you plan to stop denosumab for any reason, discuss transition therapy with your provider at least 3 months before your final dose. Transitioning to zoledronic acid 5 mg IV or alendronate 70 mg weekly is the evidence-based approach to preventing rebound bone loss. 17